Paul T. Quinlan, General Counsel of Oruka Therapeutics, Inc. (NASDAQ:ORKA), filed a Form 4 on November 20, 2026, disclosing the exercise of an employee warrant and the sale of 9,000 shares of common stock on the same date pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Warrant exercise: Quinlan exercised an employee warrant (right to buy) covering 9,000 shares of common stock at an exercise price of $7.80 per share on November 20, 2026.
  • Shares sold: A total of 9,000 shares were disposed of across four sale transactions on November 20, 2026, at weighted average prices ranging from $94.0485 to $96.60 per share.
  • 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • Remaining holdings: Following the reported transactions, Quinlan directly beneficially owned 29,995 shares of common stock.
  • Derivative securities remaining: Quinlan retained 61,996 employee warrants (right to buy) following the reported transactions, held directly.

Quinlan Exercises Warrant and Sells Shares Under Pre-Set Trading Plan

According to the Form 4 filed with the SEC, Paul T. Quinlan, serving as General Counsel of Oruka Therapeutics, Inc., reported transactions in the company's common stock on November 20, 2026. The filing indicates Quinlan first acquired 9,000 shares through the exercise of an employee warrant at a conversion price of $7.80 per share, bringing his directly held common stock position to 38,995 shares prior to the sales.

The filing then reports four separate sale transactions on the same date, collectively disposing of 9,000 shares. The sales and their weighted average prices, as disclosed, were: 3,300 shares at $94.0485 (with individual transaction prices ranging from $93.40 to $94.38), 3,000 shares at $94.7732 (prices ranging from $94.46 to $95.22), 2,500 shares at $95.9944 (prices ranging from $95.52 to $96.30), and 200 shares at $96.60 (prices ranging from $96.56 to $96.64). The filing notes that full per-share transaction detail is available upon request to Oruka Therapeutics, the company's security holders, or the SEC staff.

The filing indicates all four sales were made pursuant to a Rule 10b5-1 trading plan that Quinlan entered into on May 15, 2026. The employee warrant exercised covers common stock with an expiration date of July 14, 2034, and the filing states the warrant "vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025." The form was filed by Quinlan as a single reporting person.

What Was Disclosed

Oruka Therapeutics General Counsel Paul T. Quinlan disclosed a warrant exercise for 9,000 shares at $7.80 and the sale of 9,000 shares at weighted average prices between $94.0485 and $96.60 on November 20, 2026, under a pre-established 10b5-1 plan, leaving him with 29,995 directly held shares.